3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
5
Glioma
4
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Urothelial Cancer
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Interventions
pemigatinib
5
pembrolizumab
1
exemestane
1
erdafitinib
1
INCB 54828-101
1
Gemcitabine
1
Fulvestrant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acrocephalosyndactylia
×
erdafitinib
×
1 year
×
Clear all
NCT05567185
2026-06-05
TAR-210
Janssen Pharmaceutical K.K.
Phase 1
Active not recruiting
5 enrolled